tbuckley/cabot-search huggingface dataset:
Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon
Authors: Nicole G. Chau, Peter S. Hammerman
Journal: Clinical Cancer Research (2016)

Cetuximab-platinum chemotherapy is used for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC); however, a minority of patients benefit. Gene expression profiling (GEP) of HNSCCs with prolonged responses to cetuximab-chemotherapy demonstrate basal subtype traits including signatures of EGFR signaling and hypoxic differentiation. GEP of short-response patients show RAS activation. Clin Cancer Res; 22(15); 3710-2. ©2016 AACRSee related article by Bossi et al., p. 3961.
Abstract 5577: Text-mining methods applied to clinical records support an association between androgen deprivation therapy and subsequent cardiometabolic disease
Authors: Kevin T. Nead, Gregory L. Gaskin, Cariad Chester, Nigam H. Shah, Nicholas J. Leeper
Journal: Cancer Research (2015)

Abstract We conducted this study to examine the association of androgen deprivation therapy in the treatment of prostate cancer with future metabolic and cardiovascular disease. Here we utilize electronic medical record data from 1.8 million subjects in the Stanford Translational Research Integrated Database Environment. Specifically, we extracted ICD-9 diagnostic codes, patient medication lists and data from clinical notes using a previously validated text-analytics pipeline. Through this approach, we identified a cohort of 4,578 individuals with prostate cancer containing data on all defined covariates including Gleason score, age, race and use of antiplatelet, anticoagulant, antihypertensive and lipid lowering agents. We used multivariable logistic regression techniques to examine the association of androgen deprivation therapy use with diabetes, peripheral arterial disease, and stroke. Following prostate cancer diagnosis, there were 80 new diagnoses of diabetes, 39 new diagnoses of peripheral arterial disease and 72 new diagnoses of stroke with 409 individuals receiving androgen deprivation therapy. The use of androgen deprivation therapy to treat prostate cancer was associated with an increased risk of diabetes (odds ratio [OR] = 2.37; 95% confidence interval [CI] 1.40-4.03; P = 0.001), peripheral arterial disease (OR = 2.15; 95% CI 1.07-4.32; P = 0.032) and stroke (OR = 2.88; 95% CI 1.72-4.80; P&amp;lt;0.001). Here we further demonstrate the utility of clinical data obtained during routine care to investigate clinical hypotheses. Additionally, we add evidence to the growing body of literature linking the use of androgen deprivation therapy to future cardiovascular and metabolic disease. Citation Format: Kevin T. Nead, Gregory L. Gaskin, Cariad Chester, Nigam H. Shah, Nicholas J. Leeper. Text-mining methods applied to clinical records support an association between androgen deprivation therapy and subsequent cardiometabolic disease. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 5577. doi:10.1158/1538-7445.AM2015-5577
Oral abstract presentations
Authors: L. Pereira, G. Ruiz-Hurtado, E. Morel, A. Dominguez, J. P. Benitah, D. M. Bers, F. Lezoualc'h, A. Gomez, T. P. Collins, M. B. Sikkel, P. O' Gara, A. R. Lyon, S. E. Harding, K. T. Macleod, S. Wantha, J. E. Alard, Y. Doering, M. Drechsler, R. T. Megens, T. Hackeng, C. Weber, O. Soehnlein, B. Dietel, I. Cicha, R. Altendorf, W. G. Daniel, C. D. Garlichs, U. Mukherjee, S. B. Ong, S. M. Davidson, G. Szabadkai, D. M. Yellon, D. J. Hausenloy, M. T. Neary, A. R. Hall, E. Hirst, S. B. Ong, T. J. Mohun, D. J. Hausenloy, R. A. Breckenridge, A. Akhmedov, G. G. Camici, S. Stivala, E. W. Holy, A. Breitenstein, C. Lohmann, J.-H. Beer, F. C. Tanner, C. M. Matter, T. F. Luescher, M. Hulsmans, B. Geeraert, T. Arnould, C. Tsatsanis, P. Holvoet, N. Hermida, A. Markl, J. Hamelet, P. Herijgers, S. Horman, G. Noppe, C. Beauloye, M. Van Bilsen, C. Dessy, J.-L. Balligand, R. Del Giorno, I. Moreno Velasquez, K. Leander, P. Frumento, M. Vikstrom, M. Pirro, M. R. Mannarino, E. Mannarino, U. De Faire, B. Gigante, B. Chaudhry, P. Chrystal, D. J. Henderson, F. G. Fulcoli, L. Chen, S. Martucciello, E. Illingworth, A. Baldini, M. Mavroidis, C. Davos, S. Psarras, A. Varela, I. Kostavasili, Y. Capetanaki, K. Engstrom Klarstrom, C. Skoglund, H. Kalvegren, T. Bengtsson, F. Drawnel, D. Wachten, J. D. Molkentin, I. Sjaastad, N. Liu, K. Mikoshiba, M. D. Bootman, H. L. Roderick, K. Di Gregoli, R. Salter, J. L. Johnson
Journal: Cardiovascular Research (2012)
Acute Inpatient Cancer Rehabilitation Unit (ACRU) outcomes at an NCI-Comprehensive Cancer Center
Authors: K. Y. Shin
Journal: Journal of Clinical Oncology (2004)

8149 Background: Cancer rehabilitation is an important but often underutilized treatment in the comprehensive care of the cancer patient. Cancer patients have varying degrees of access to rehabilitation services throughout the country. We report Acute Inpatient Cancer Rehabilitation Unit (ACRU) outcomes at MD Anderson Cancer Center, which is the only NCI-comprehensive cancer center to have an inpatient rehabilitation unit dedicated solely to cancer patients. Methods: We retrospectively reviewed the inpatient medical records of consecutive inpatients admitted to the ACRU from September 2002-August 2003 for the following information: patient age, sex, primary tumor type, rehab diagnoses, length of stay, discharge destination, and payer source. Results: From September 2002-August 2003, the Physical Medicine and Rehabilitation service at MD Anderson had 865 inpatient consultations, 403 of whom were admitted to the ACRU for a total of 4101 days with a mean stay of 10 days. 218 were male (54%). Mean patient age was 61. Admission criteria included medical stability and the ability to tolerate 3 hours a day of therapies. Primary tumors were brain and spine 113 (28%), hematologic 56 (14%), genitourinary 56 (14%), lung 43 (10%), orthopedic 32 (8%), gastrointestinal 24 (6%), breast 20 (5%), head and neck 16 (4%), and other 44 (11%). Distribution of discharges included home 299 (74%), back to primary acute service 81 (20%), ICU 8 (2%), skilled nursing facility 7 (2%), nursing home 7 (2%), long term acute care 2 (<1%), death 1 (<1%). Brain and spine patients commonly had the rehab diagnoses hemiparesis or spinal cord injury. Hematologic patients' rehab diagnoses were more frequently asthenia and dyspnea on exertion. Most patients carried the rehab diagnosis of gait abnormality. Payer source distribution included Medicare 177 (44%), private insurance 145 (36%), HMO 36 (9%), Medicaid 20 (5%), and indigent status 24 (6%), with an overall denial rate of 0%. Conclusions: An active inpatient clinical service possessing a wide variety of tumor types was financially viable and able to successfully discharge to home 74% of its patients. No significant financial relationships to disclose.
Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies
Authors: Hua Jing, Claudia Weidensteiner, Wilfried Reichardt, Simone Gaedicke, Xuekai Zhu, Anca-Ligia Grosu, Hisataka Kobayashi, Gabriele Niedermann
Journal: Theranostics (2016)

Near-infrared photoimmunotherapy (NIR-PIT), which employs monoclonal antibody (mAb)-phototoxic phthalocyanine dye IR700 conjugates, permits the specific, image-guided and spatiotemporally controlled elimination of tumor cells. Here, we report the highly efficient NIR-PIT of human tumor xenografts initiated from patient-derived cancer stem cells (CSCs). Using glioblastoma stem cells (GBM-SCs) expressing the prototypic CSC marker AC133/CD133, we also demonstrate here for the first time that NIR-PIT is highly effective against brain tumors. The intravenously injected theranostic AC133 mAb conjugate enabled the non-invasive detection of orthotopic gliomas by NIR fluorescence imaging, and reached AC133+ GBM-SCs at the invasive tumor front. AC133-targeted NIR-PIT induced the rapid cell death of AC133+ GBM-SCs and thereby strong shrinkage of both subcutaneous and invasively growing brain tumors. A single round of NIR-PIT extended the overall survival of mice with established orthotopic gliomas by more than a factor of two, even though the harmless NIR light was applied through the intact skull. Humanised versions of this theranostic agent may facilitate intraoperative imaging and histopathological evaluation of tumor borders and enable the highly specific and efficient eradication of CSCs.
FRI0329 A Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Arhalofenate in Combination with Febuxostat when Treating Hyperuricemia Associated with Gout: Table 1
Authors: A. Steinberg, B. Vince, Y.-J. Choi, R. Martin, C. McWerther, P. Boudes
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Context</h3> This volunteering service supports patients and families coping with a life-limiting illness. It was established in 2015 following a study evaluated by Lancaster University, funded by the Centre for Social Action, Cabinet Office. It was one of six project sites to set up a pilot service to evaluate support for end of life patients by social action volunteers. In collaboration with local partners volunteers were recruited and completed training following a thorough recruitment process. Patients were recruited onto pilot and consented to an assessment of their support needs. Patients and carers were asked by the University to complete questionnaires on carer burden, quality of life, loneliness and social support whilst being supported for twelve weeks by volunteers. <h3>Aim</h3> To provide practical and emotional support for isolated individuals and their families, within their home who have a palliative diagnosis. The project is managed by a co-coordinator who visits individuals at home and completes assessments to discuss the support required. Interests and background are taken into account to match with an appropriate volunteer. Regular reviews are held to ensure the partnership is working. Weekly 1–3 hours of support provides: Befriending, companionship Shopping or social outings Daily errands and chores Accompanying individuals to hospital and GP appointments Assisting with social media to keep in touch with distant relatives. <h3>Evaluation and sustainability</h3> The study is evaluated by Lancaster University by end of June 2016. It is hoped that this will provide favourable evidence for CCGs to future fund. The hospice carried out its own evaluation, a user survey which was presented to the board of trustees which resulted in backed funding for a permanent coordinator post. Development of the service and role of the Herts Neighbour is being progressed to provide enablement and bereavement support.
The Salivary Sodium-Potassium Ratio
Authors: David P. Lauler, Roger B. Hickler, George W. Thorn
Journal: New England Journal of Medicine (1962)

THE high incidence of hypertension in cases of primary aldosteronism,1 the recent association of an elevated aldosterone secretory rate in malignant hypertension2 and the case reports of aldosteronism associated with unilateral renal arterial stenosis3 have all focused clinical attention on the functional status of the adrenal gland in hypertensive subjects. However, this investigative enthusiasm is often dampened by duration and cost of sodium-potassium metabolic-balance studies4 and limited availability of the determination of tritium-labeled aldosterone secretory rate.5 A definite need is thus apparent for a "screening" procedure that can be applied to hypertensive subjects, to select those warranting further and more . . .
Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants
Authors: Muhammed O Afolabi, Alfred B Tiono, Uche J Adetifa, Jean Baptiste Yaro, Abdoulie Drammeh, Issa Nébié, Carly Bliss, Susanne H Hodgson, Nicholas A Anagnostou, Guillaume S Sanou, Ya Jankey Jagne, Oumarou Ouedraogo, Casimir Tamara, Nicolas Ouedraogo, Mirielle Ouedraogo, Jainaba Njie-Jobe, Amidou Diarra, Christopher JA Duncan, Riccardo Cortese, Alfredo Nicosia, Rachel Roberts, Nicola K Viebig, Odile Leroy, Alison M Lawrie, Katie L Flanagan, Beate Kampman, Philip Bejon, Egeruan B Imoukhuede, Katie J Ewer, Adrian VS Hill, Kalifa Bojang, Sodiomon B Sirima
Journal: Molecular Therapy (2016)

Malaria remains a significant global health burden and a vaccine would make a substantial contribution to malaria control. Chimpanzee Adenovirus 63 Modified Vaccinia Ankara Multiple epitope thrombospondin adhesion protein (ME-TRAP) and vaccination has shown significant efficacy against malaria sporozoite challenge in malaria-naive European volunteers and against malaria infection in Kenyan adults. Infants are the target age group for malaria vaccination; however, no studies have yet assessed T-cell responses in children and infants. We enrolled 138 Gambian and Burkinabe children in four different age-groups: 2-6 years old in The Gambia; 5-17 months old in Burkina Faso; 5-12 months old, and also 10 weeks old, in The Gambia; and evaluated the safety and immunogenicity of Chimpanzee Adenovirus 63 Modified Vaccinia Ankara ME-TRAP heterologous prime-boost immunization. The vaccines were well tolerated in all age groups with no vaccine-related serious adverse events. T-cell responses to vaccination peaked 7 days after boosting with Modified Vaccinia Ankara, with T-cell responses highest in 10 week-old infants. Heterologous prime-boost immunization with Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara ME-TRAP was well tolerated in infants and children, inducing strong T-cell responses. We identify an approach that induces potent T-cell responses in infants, which may be useful for preventing other infectious diseases requiring cellular immunity.
AB0571 Hyperviscosity is Associated with Hematological Features and Vasculitis in Primary SjÖgren's Syndrome Patients
Authors: G. Hernandez-Molina, P. Bermúdez-Bermejo
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Hyperglobulinemia is a frequent serological abnormality in primary Sjögren9s Syndrome (pSS) and might cause hyperviscosity. However a classic hyperviscosity syndrome (HVS) is rarely seen in these patients. <h3>Objectives</h3> To compare the clinical and serological profile among three groups of pSS patients: 1) with HVS, 2) with high serum viscosity without HVS and 3) with normal viscosity. <h3>Methods</h3> We included four pSS patients with HVS and 62 randomly patients with pSS according to the AECG criteria. HVS was defined as the presence of bleeding diathesis, visual abnormalities and neurologic deficits in the presence of a high serum viscosity (&gt;4 c.p). High viscosity was defined as a serum viscosity &gt;1.9 c.p. The ever presence of glandular (ocular, oral, parotid enlargement), extraglandular (splenomegaly, lymphadenopathy, non-erosive arthritis, myositis, Raynaud, skin vasculitis, pulmonary involvement, renal involvement, gastrointestinal involvement, neutropenia &lt;1000, thrombocytopenia &lt;100000, lymphopenia&lt;10000 and leucopenia&lt;3500) and serologic features (RF, ANA, ant-Ro and anti-La) were registered from the medical charts. We scored the ESSDAI activity index at the last visit. We used X<sup>2</sup> and U-Mann Whitney tests. <h3>Results</h3> Patients were predominantly females (95%) with a median age of 54 years and median disease duration of 9 years (0-42). Thirty-four patients (51.5%) had high viscosity, including the 4 patients with HVS. All the HVS cases were diagnosed concomitantly with the onset of SS. HVS patients have higher titers of IgG (6100 vs. 1547, p&lt;0.001), IgM (1715 vs. 175, p&lt;0.001), IgA (1330 vs. 318, p&lt;0.001) and serum viscosity (14 vs. 1.9 c.p., p&lt;0.001) than patients without HVS (n=61). In addition they had more vasculitis (50% vs. 8.3% p=0.05), neutropenia (100% vs. 6.7%, p&lt;0.001,) lymphopenia (75% vs. 23.3% p=0.05), leucopenia (75% vs. 11.7%, p=0.01), splenomegaly (50% vs. 5%, p=0.02) and received more frequently prednisone (100% vs. 43%, p=0.04) and azathioprine (100% vs. 16.7%, p=0.002). The high viscosity group had a median serum viscosity of 2.2 c.p (range 2-3). This group had increased IgG, IgM and IgA levels, (p&lt;0.01), a higher median ESSDAI (2 vs. 1, p&lt;0.001) score and more vasculitis (16.7% vs. 0%, p=0.05) when compared with patients with normal viscosity. <h3>Conclusions</h3> HVS in SS patients is associated with hematologic features, vasculitis and splenomegaly. The presence of vasculitis should alert about the coexistence of high viscosity values. <h3>Acknowledgements</h3> Grant CB SEP/CONACYT <h3>Disclosure of Interest</h3> None declared
Immunotherapy tablet helps control asthma in people with house dust mite allergy
Authors: Jacqui Wise
Journal: BMJ (2016)

Patients with house dust mite allergy related asthma showed improvements in asthma control when given sublingual allergen immunotherapy on top of their usual medicine, research published in JAMA has found.1

Sublingual allergen immunotherapy involves small doses of an allergen contained in a soluble tablet placed under the tongue. In this case the tablet contained extracts from two species of cultivated house dust mite. House dust mite sensitisation is present in as many as half of patients with asthma, and exposure to the house dust mite allergen …
Possible role of antidepressants in precipitating mania and hypomania in recurrent depression
Authors: D J Kupfer, L L Carpenter, E Frank
Journal: American Journal of Psychiatry (1988)

This prospective study examined the incidence of mania or hypomania in 230 patients with recurrent depression treated with imipramine. Overall, only six individuals (2.6%) developed hypomania, representing 0.9% of those in the acute phase and 2.5% of those in the continuation phase of drug treatment. Patients with a history of bipolar II depression (N = 33) did not have a greater incidence of hypomania than those with unipolar depression (N = 197). Younger patients did not switch to hypomania more rapidly than older ones, and women were not more likely to switch than men. Systematic assessment of mania, stringent diagnostic criteria, and the recurrent nature of the sample may account for this low incidence of hypomania compared to that reported by other investigators.
Case 47-1991
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, H.C. Hoover, J.X. O'Connell
Journal: New England Journal of Medicine (1991)

Presentation of CaseA 68-year-old man was admitted to the hospital because of headache, nausea, vomiting, and abdominal pain.The patient was in stable health until the day of admission, when he failed to appear for breakfast and lunch at a nursing home where he resided. The patient was found in his room with a severe headache, followed by nausea, vomiting, and abdominal pain. En route to this hospital in an ambulance the patient became intermittently somnolent and then extremely agitated and confused. He was admitted to the hospital.The patient was a native of Latvia, who had immigrated to . . .
Behavioral Interventions in Treating Anticipatory Nausea and Vomiting
Authors: Colmar Figueroa-Moseley, Pascal Jean-Pierre, Joseph A. Roscoe, Julie L. Ryan, Sadhna Kohli, Oxana G. Palesh, Elizabeth P. Ryan, Jennifer Carroll, Gary R. Morrow
Journal: Journal of the National Comprehensive Cancer Network (2007)

Anticipatory nausea and vomiting (ANV) is associated with a significant reduction in the quality of life for many chemotherapy patients. The use of 5-hydroxytryptamine type 3 receptor antagonists provides some relief for chemotherapy-induced nausea and vomiting, but does not seem to control ANV. Nonpharmacologic approaches, which include behavioral interventions, may provide the greatest promise in relieving symptoms. Little evidence supports the use of complementary and alternative methods, such as acupuncture and acupressure, in relieving ANV. Behavioral interventions, especially progressive muscle relaxation training and systematic desensitization, should be considered important methods for preventing and treating ANV.
The Kisspeptin and GPR54 ligand-receptor pair are associated with favorable prognosis and clear cell subtype in human ovarian carcinoma
Authors: Leah Prentice, Christian Klausen, Steve Kalloger, Martin Kobel, Steven McKinney, Ken Swenerton, Jennifer Santos, Blake Gilks, Peter Leung, David Huntsman, Samuel Aparicio
Journal: Clinical Cancer Research (2007)

B73   GPR54 is a G-protein coupled receptor that stimulates release of GnRH upon binding with its secreted ligands, the Kisspeptins. The Kisspeptins have also been credited with inducing an anti-metastatic phenotype in tumor cells in vitro. This study characterizes expression of Kisspeptin and GPR54 in clinical ovarian tumor samples using the immunohistochemical method on a tissue microarray (TMA). The TMA consisted of 518 early stage ovarian carcinomas, all with linked clinical outcome data and was scored using a staining intensity scale of 0 (negative), +1 (mild-moderate), and +2 (strong). For statistical analysis, strong staining cases were considered either Kisspeptin or GPR54 positive and designated as 1, while all other cases were considered negative and designated 0. Kisspeptin positive and GPR54 positive cases show a favorable prognosis in univariable disease specific survival (p=0.0023, p=0.0092), as well as in overall survival (p=0.0006, p=0.0002). Further, Kissspeptin is an independent marker for favorable prognosis is disease specific and overall survival (p=0.0046, p=0.0170), while GPR54 is independent in overall survival only (p=0.0303). Both Kisspeptin and GPR54 positive cases are strongly associated with the ovarian carcinoma clear cell subtype (p
Endogenous Cortisol and Lung Damage in a Predominantly Smoking Population
Authors: KIMBERLEY D. CLARK, NIGEL WARDROBE-WONG, PHILLIP D. SNASHALL
Journal: American Journal of Respiratory and Critical Care Medicine (1999)

We examined the association of endogenous corticosteroid status with lung structure and function in a cross-sectional and longitudinal study in response to a recent finding of a relationship between plasma cortisol and rate of annual decline in airway function. We recruited 74 cigarette-smoking and 20 never-smoking volunteers 35 to 65 yr of age after publicity in local media. Exclusion criteria were FEV1 < 1.5 L or a history of airway disease. We performed spirometry and a high resolution CT lung scan and measured CO transfer, serum cortisol, and 24-h urinary cortisol excretion. There were no differences in serum or urinary cortisol between those with and those without low FEV1, low Kco, or high resolution CT (HRCT) emphysema, except that urinary cortisol was 19% higher in subjects with HRCT emphysema (p = 0.05). Log urinary cortisol/body weight was negatively correlated with Kco (p = 0.000) and Kco was lower in the highest tertile of urinary cortisol (p = 0.001). Subjects were restudied after 520 ± 69 d. Changes in FEV1 and Kco showed no significant correlations with serum or urinary cortisol. We conclude that airway function does not relate to serum or urinary cortisol, but there may be a relationship between cortisol excretion and emphysema.